Implication of aspirin resistance: Simple laboratory finding or important clinical criteria?.
- Author:
Young Hoon JEONG
1
Author Information
1. Department of Internal Medicine, College of Medicine, Gyeongsang National University Hospital, Jinju, Korea.
- Publication Type:Editorial
- Keywords:
Aspirin resistance;
VerifyNow-Aspirin;
Tailored antiplatelet therapy
- MeSH:
Aspirin;
Blood Platelets;
Humans;
Light;
Prospective Studies;
Stents;
Thromboxane B2
- From:Korean Journal of Medicine
2009;76(6):682-684
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Aspirin resistance defined by light transmittance aggregometry (LTA) or urinary 11-dehydro-thromboxane B2 has been associated with an increased risk of adverse clinical events. However, aspirin resistance based on the point-of-care VerifyNow-Aspirin assay (aspirin reaction unit > or = 550) shows poor sensitivity compared with LTA. In aspirin-treated patients, activation by cyclooxygenase- independent pathways may be associated with residual platelet reactivity, which may cause adverse clinical outcomes in some portion. A large-scale, prospective study using several platelet function assays should be performed to establish the long-term clinical significance of antiplatelet resistance in Korean patients treated with coronary stenting. Accordingly, we can apply tailored antiplatelet therapy in resistant patients.
